Stephen Fox, DPhil - Publications

Affiliations: 
1993-1995 University of Oxford, Oxford, United Kingdom 
Website:
https://www.linkedin.com/in/stephen-fox-ab508717/?originalSubdomain=au

185 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, ... ... Fox S, et al. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. European Journal of Cancer (Oxford, England : 1990). 173: 178-193. PMID 35933885 DOI: 10.1016/j.ejca.2022.06.011  0.32
2022 van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S. Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research : Bcr. 24: 50. PMID 35841108 DOI: 10.1186/s13058-022-01539-7  0.31
2022 Doig KD, Fellowes A, Scott P, Fox SB. Tumour mutational burden: an overview for pathologists. Pathology. PMID 35153070 DOI: 10.1016/j.pathol.2021.11.008  0.773
2021 Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, ... ... Fox SB, et al. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology. PMID 34937664 DOI: 10.1016/j.pathol.2021.11.002  0.56
2021 Bouchè V, Aldegheri G, Donofrio CA, Fioravanti A, Roberts-Thomson S, Fox SB, Schettini F, Generali D. BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives? Frontiers in Oncology. 11: 772052. PMID 34804975 DOI: 10.3389/fonc.2021.772052  0.496
2021 Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Archiv : An International Journal of Pathology. PMID 34458944 DOI: 10.1007/s00428-021-03190-7  0.352
2020 Kalaw E, Lim M, Kutasovic JR, Sokolova A, Taege L, Johnstone K, Bennett J, Saunus JM, Niland C, Ferguson K, Gresshoff I, Bettington M, Pathmanathan N, Tse GM, Papadimos D, ... ... Fox S, et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. British Journal of Cancer. PMID 32939056 DOI: 10.1038/s41416-020-01065-3  0.317
2020 van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research : Bcr. 22: 91. PMID 32811538 DOI: 10.1186/s13058-020-01328-0  0.35
2020 Cheasley D, Devereux L, Hughes S, Nickson C, Procopio P, Lee G, Li N, Pridmore V, Elder K, Bruce Mann G, Kader T, Rowley SM, Fox SB, Byrne D, Saunders H, et al. The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. Npj Breast Cancer. 6: 34. PMID 32802943 DOI: 10.1038/s41523-020-00176-7  0.362
2020 Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, ... ... Fox SB, et al. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment. PMID 32770287 DOI: 10.1007/s10549-020-05856-3  0.775
2020 Whittle JR, Vaillant F, Surgenor E, Policheni AN, Giner G, Capaldo BD, Chen HR, Liu HK, Dekkers JF, Sachs N, Clevers H, Fellowes A, Green T, Xu H, Fox SB, et al. Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32245900 DOI: 10.1158/1078-0432.Ccr-19-1872  0.351
2020 Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, Fox SB, Giudici F, Generali D. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. PMID 32060782 DOI: 10.1007/s10549-020-05565-x  0.563
2020 Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, et al. The 2019 WHO classification of tumours of the breast. Histopathology. PMID 32056259 DOI: 10.1111/his.14091  0.315
2019 Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, Henderson MA, Nightingale SS, Ho KM, Myles PS, Fox S, Riedel B, Sloan EK. Pre-operative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II randomized trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31754048 DOI: 10.1158/1078-0432.CCR-19-2641  0.311
2019 Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology. PMID 31668406 DOI: 10.1016/j.pathol.2019.08.006  0.637
2019 Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, ... Fox S, et al. Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research. 79: 3008. PMID 31160311 DOI: 10.1158/0008-5472.Can-19-1133  0.309
2019 Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, et al. Combined tumor sequencing and case/control analyses of RAD51C in breast cancer. Journal of the National Cancer Institute. PMID 30949688 DOI: 10.1093/Jnci/Djz045  0.346
2019 Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, ... Fox SB, et al. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. The Journal of Pathology. PMID 30843206 DOI: 10.1002/path.5262  0.342
2018 McCart Reed AE, Kalaw E, Nones K, Bettington M, Lim M, Bennett J, Johnstone K, Kutasovic JR, Saunus JM, Kazakoff S, Xu Q, Wood S, Holmes O, Leonard C, Reid LE, ... ... Fox S, et al. Phenotypic and molecular dissection of Metaplastic Breast Cancer and the prognostic implications. The Journal of Pathology. PMID 30350370 DOI: 10.1002/path.5184  0.376
2018 Kader T, Hill P, Opeskin K, Goode D, Elder K, Pang J, Fox S, Mann G, Campbell I, Gorringe K. Abstract PD1-12: Identification of copy number alterations associated with the progression of high risk premalignant breast lesions to breast carcinoma Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd1-12  0.338
2018 Gorringe K, Hughes S, Nickson C, Devereux L, Pridmore V, Rowley S, Byrne D, Cheasley D, Kavanagh A, Mann G, Fox S, Campbell I. Abstract P3-04-06: Genomic analysis of cancers arising in breasts with different mammographic density Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-04-06  0.348
2017 Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA, Clyne C, Gorringe KL, Dobrovic A, Fox SB. LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget. 8: 83626-83636. PMID 29137369 DOI: 10.18632/oncotarget.18886  0.411
2017 Gorringe KL, Fox SB. Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. Frontiers in Oncology. 7: 248. PMID 29109942 DOI: 10.3389/fonc.2017.00248  0.327
2017 Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881. PMID 29108271 DOI: 10.18632/oncotarget.20239  0.813
2017 Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB. BRCA2 carriers with male breast cancer show elevated tumour methylation. Bmc Cancer. 17: 641. PMID 28893223 DOI: 10.1186/s12885-017-3632-7  0.333
2017 Paquet-Fifield S, Roufail S, Zhang YF, Sofian T, Byrne DJ, Coughlin PB, Fox SB, Stacker SA, Achen MG. The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. Growth Factors (Chur, Switzerland). 1-15. PMID 28697634 DOI: 10.1080/08977194.2017.1349765  0.314
2017 Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in Triple Negative Breast Cancers. Histopathology. PMID 28211079 DOI: 10.1111/his.13187  0.373
2017 Jeffreena Miranda P, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, et al. MDM4 is a rational target for treating breast cancers with mutant p53. The Journal of Pathology. PMID 28097652 DOI: 10.1002/path.4877  0.353
2016 Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. PMID 28049579 DOI: 10.1016/j.pathol.2016.10.010  0.376
2016 Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, et al. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". Plos Medicine. 13: e1002204. PMID 28027312 DOI: 10.1371/journal.pmed.1002204  0.314
2016 Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. The Lancet. Oncology. PMID 27964843 DOI: 10.1016/S1470-2045(16)30631-3  0.387
2016 Huo CW, Waltham M, Khoo C, Fox SB, Hill P, Chen S, Chew GL, Price JT, Nguyen CH, Williams ED, Henderson M, Thompson EW, Britt KL. Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. Breast Cancer Research : Bcr. 18: 106. PMID 27776557 DOI: 10.1186/s13058-016-0767-4  0.322
2016 Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, von Neumann-Cosel V, Bilous M. Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. Pathology. PMID 27567228 DOI: 10.1016/j.pathol.2016.05.007  0.332
2016 Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, ... Fox SB, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. Breast (Edinburgh, Scotland). 29: 55-61. PMID 27428471 DOI: 10.1016/j.breast.2016.07.003  0.75
2016 Roviello G, Ravelli A, Ida Fiaschi A, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D. Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology & Hepatology. PMID 27376400 DOI: 10.1080/17474124.2016.1209407  0.498
2016 Roviello G, Ravelli A, Barni S, Petrelli F, Bottini A, Fox SB, Generali D. Is it time for everolimus-based combination in castration-resistant prostate cancer? Future Oncology (London, England). PMID 27250597 DOI: 10.2217/fon-2016-0136  0.457
2016 Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone CN, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, ... Fox SB, et al. E3 ligase E6AP represses breast cancer metastasis via regulation of ECT2-Rho signalling. Cancer Research. PMID 27231202 DOI: 10.1158/0008-5472.Can-15-1553  0.404
2016 Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer (Oxford, England : 1990). 61: 111-121. PMID 27162152 DOI: 10.1016/j.ejca.2016.04.002  0.479
2016 Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 68: 110-8. PMID 26768033 DOI: 10.1111/his.12862  0.312
2015 Huang KT, Mikeska T, Li J, Takano EA, Millar EK, Graham PH, Boyle SE, Campbell IG, Speed TP, Dobrovic A, Fox SB. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. Bmc Cancer. 15: 669. PMID 26452468 DOI: 10.1186/s12885-015-1676-0  0.335
2015 Cappelletti MR, Gnetti L, Santini D, Spada D, Fox SB, Generali D. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? Oncoscience. 2: 567-9. PMID 26244161 DOI: 10.18632/ONCOSCIENCE.168  0.509
2015 Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Ying Lee Y, Hiddingh S, Rogers TM, Teunisse AF, Herold MJ, Marine JC, Fox SB, Jochemsen A, et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death & Disease. 6: e1821. PMID 26181202 DOI: 10.1038/cddis.2015.173  0.379
2015 Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology. PMID 26118394 DOI: 10.1111/his.12765  0.555
2015 Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, et al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute. Monographs. 2015: 90-6. PMID 26063896 DOI: 10.1093/jncimonographs/lgv023  0.632
2015 Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, ... ... Fox SB, et al. Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response. Journal of the National Cancer Institute. Monographs. 2015: 64-6. PMID 26063890 DOI: 10.1093/jncimonographs/lgv018  0.798
2015 Generali D, Fox SB, Cristofanilli M, Bianchini G, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M. Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute. Monographs. 2015: 1-3. PMID 26063875 DOI: 10.1093/jncimonographs/lgv022  0.498
2015 Takano EA, Hunter SM, Campbell IG, Fox SB. Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. Journal of Clinical Pathology. 68: 362-7. PMID 25713418 DOI: 10.1136/jclinpath-2014-202824  0.314
2015 Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, ... ... Fox SB, et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. British Journal of Cancer. 112: 52-60. PMID 25461806 DOI: 10.1038/bjc.2014.563  0.82
2014 Kato T, Pezzella F, Steers G, Campo L, Leek RD, Turley H, Kameoka S, Nishikawa T, Harris AL, Gatter KC, Fox S. Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology. 7: 7967-78. PMID 25550840  0.82
2014 Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T, Fellowes A, Dobrovic A, Fox SB. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. British Journal of Cancer. 111: 2351-60. PMID 25490678 DOI: 10.1038/bjc.2014.511  0.308
2014 Trabert B, Falk RT, Figueroa JD, Graubard BI, Garcia-Closas M, Lissowska J, Peplonska B, Fox SD, Brinton LA. Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland. Cancer Causes & Control : Ccc. 25: 1587-93. PMID 25189422 DOI: 10.1007/s10552-014-0461-8  0.31
2014 Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. British Journal of Cancer. 111: 46-54. PMID 24874483 DOI: 10.1038/bjc.2014.236  0.641
2014 Bedussi F, Bottini A, Memo M, Fox SB, Sigala S, Generali D. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall? Expert Opinion On Therapeutic Targets. 18: 665-78. PMID 24833241 DOI: 10.1517/14728222.2014.898064  0.599
2014 Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, ... ... Fox SB, et al. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". Breast Cancer Research and Treatment. 144: 113-21. PMID 24469643 DOI: 10.1007/s10549-014-2840-y  0.555
2014 Deb S, Johansson I, Byrne D, Nilsson C, Investigators k, Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB. Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 27: 1223-30. PMID 24457463 DOI: 10.1038/Modpathol.2013.231  0.333
2014 Masoud Rahbari R, Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski J, Verschoor S, KA Miller E, Van der Spek P, Reis-Filho J, Ramsay R, O'Toole S, McNeil C, ... ... Fox S, et al. Enhanced RAD21 Cohesin Expression Confers Poor Prognosis and Resistance to Chemotherapy in High Grade Luminal, Basal, and HER 2 Breast Cancers International Journal of Radiation Oncology*Biology*Physics. 90: S812. DOI: 10.1016/J.IJROBP.2014.05.2343  0.362
2013 Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, Kyle FJ, Thomas RS, Launchbury R, Hua H, Callaghan HB, Carroll JS, Charles Coombes R, Zwart W, Buluwela L, et al. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Research. 41: 10228-40. PMID 24049078 DOI: 10.1093/nar/gkt827  0.308
2013 Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S, Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB. The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5740-8. PMID 23969937 DOI: 10.1158/1078-0432.CCR-13-1712  0.804
2013 Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G. Triple negative breast cancers have a reduced expression of DNA repair genes. Plos One. 8: e66243. PMID 23825533 DOI: 10.1371/journal.pone.0066243  0.56
2013 Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. British Journal of Cancer. 108: 1587-92. PMID 23579222 DOI: 10.1038/bjc.2013.151  0.788
2013 Samarajeewa NU, Yang F, Docanto MM, Sakurai M, McNamara KM, Sasano H, Fox SB, Simpson ER, Brown KA. HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Research : Bcr. 15: R30. PMID 23566437 DOI: 10.1186/bcr3410  0.376
2013 McCormack M, Rosa CS, Murphy M, Fox SB. HER2-positive breast cancer metastatic to intracranial meningioma: a case report. Journal of Clinical Pathology. 66: 633-4. PMID 23436926 DOI: 10.1136/jclinpath-2013-201455  0.329
2012 Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. Bmc Cancer. 12: 510. PMID 23146383 DOI: 10.1186/1471-2407-12-510  0.315
2012 Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget. 3: 893-906. PMID 23097685  0.346
2012 Nguyen BT, Deb S, Fox S, Hill P, Collins M, Chua BH. A prospective pathologic study to define the clinical target volume for partial breast radiation therapy in women with early breast cancer. International Journal of Radiation Oncology, Biology, Physics. 84: 1116-22. PMID 22543203 DOI: 10.1016/j.ijrobp.2012.02.038  0.324
2012 Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I, McKay MJ, Fox SB. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Research : Bcr. 14: R69. PMID 22537934 DOI: 10.1186/bcr3176  0.339
2012 Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, ... ... Fox S, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 134-47. PMID 22144499 DOI: 10.1158/1055-9965.Epi-11-0775  0.359
2012 Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America. 109: 2766-71. PMID 21768359 DOI: 10.1073/pnas.1104778108  0.611
2011 Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, ... ... Fox S, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 13: R110. PMID 22053997 DOI: 10.1186/Bcr3052  0.326
2011 Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, ... ... Fox SB, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute. Monographs. 2011: 147-51. PMID 22043063 DOI: 10.1093/jncimonographs/lgr037  0.649
2011 Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 111-5. PMID 22043055 DOI: 10.1093/jncimonographs/lgr035  0.536
2011 Generali D, Symmans WF, Berruti A, Fox SB. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 99-102. PMID 22043052 DOI: 10.1093/jncimonographs/lgr030  0.566
2011 Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, Bersiga A, Dogliotti L, Fox SB, Harris AL, Bottini A. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. Journal of the National Cancer Institute. Monographs. 2011: 67-70. PMID 22043044 DOI: 10.1093/jncimonographs/lgr029  0.62
2011 Huang KT, Takano EA, Mikeska T, Byrne DJ, Dobrovic A, Fox SB. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Research and Treatment. 130: 319-29. PMID 21755341 DOI: 10.1007/s10549-011-1657-1  0.375
2011 Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, Fox SB. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research : Bcr. 13: R47. PMID 21521526 DOI: 10.1186/bcr2869  0.553
2011 Shaida N, Chan P, Turley H, Jones CM, Kanga S, Ritchie RW, Malone PR, Harris AL, Fox SB. Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis. The Journal of Urology. 185: 1513-8. PMID 21334674 DOI: 10.1016/j.juro.2010.12.001  0.664
2011 Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DD, Harvey KF. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30: 2810-22. PMID 21317925 DOI: 10.1038/onc.2011.8  0.325
2011 Chan P, Möller A, Liu MC, Sceneay JE, Wong CS, Waddell N, Huang KT, Dobrovic A, Millar EK, O'Toole SA, McNeil CM, Sutherland RL, Bowtell DD, Fox SB. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research : Bcr. 13: R19. PMID 21306611 DOI: 10.1186/bcr2828  0.455
2011 Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research : Bcr. 13: R16. PMID 21291529 DOI: 10.1186/bcr2825  0.832
2011 Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski JM, Verschoor S, Millar EK, van der Spek P, Reis-Filho JS, Ramsay RG, O'Toole SA, McNeil CM, Sutherland RL, ... ... Fox SB, et al. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research : Bcr. 13: R9. PMID 21255398 DOI: 10.1186/bcr2814  0.342
2011 Davies JQ, Lin HH, Stacey M, Yona S, Chang GW, Gordon S, Hamann J, Campo L, Han C, Chan P, Fox SB. Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncology Reports. 25: 619-27. PMID 21174063 DOI: 10.3892/Or.2010.1117  0.408
2011 Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 157-67. PMID 21076464 DOI: 10.1038/modpathol.2010.200  0.354
2011 McKay M, Xu H, Yan M, Yan Y, Ramsay R, Sutherland R, Fox S. 755 poster ENHANCED RAD21 COHESIN EXPRESSION CONFERS POOR PROGNOSIS AND RESISTANCE TO CHEMOTHERAPY IN HIGH GRADE LUMINAL, BASAL AND HER2 BREAST CANCERS Radiotherapy and Oncology. 99: S299. DOI: 10.1016/S0167-8140(11)70877-5  0.366
2010 Margariti N, Fox SB, Bottini A, Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? Breast Cancer Research and Treatment. 128: 599-606. PMID 20945086 DOI: 10.1007/s10549-010-0986-9  0.521
2010 Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research : Bcr. 12: 207. PMID 20804570 DOI: 10.1186/bcr2607  0.38
2010 Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment. 123: 795-804. PMID 20680681 DOI: 10.1007/s10549-010-1063-0  0.826
2010 Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, ... ... Fox S, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research : Bcr. 12: R46. PMID 20604919 DOI: 10.1186/Bcr2603  0.315
2010 Yan M, Rayoo M, Takano EA, Fox SB. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Research and Treatment. 126: 395-405. PMID 20490651 DOI: 10.1007/s10549-010-0941-9  0.378
2010 Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Research. 70: 1573-84. PMID 20145130 DOI: 10.1158/0008-5472.CAN-09-3237  0.607
2010 Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment. 124: 79-88. PMID 20054642 DOI: 10.1007/s10549-009-0714-5  0.643
2010 Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment. 123: 661-77. PMID 19960244 DOI: 10.1007/S10549-009-0653-1  0.306
2010 Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, et al. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer. Journal International Du Cancer. 126: 1445-53. PMID 19676041 DOI: 10.1002/ijc.24826  0.448
2009 Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer. 101: 1749-57. PMID 19844231 DOI: 10.1038/sj.bjc.6605368  0.823
2009 Huang KT, Dobrovic A, Fox SB. No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. Bmc Research Notes. 2: 194. PMID 19778456 DOI: 10.1186/1756-0500-2-194  0.33
2009 Yan M, Rayoo M, Takano EA, Thorne H, Fox SB. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. British Journal of Cancer. 101: 1168-74. PMID 19724277 DOI: 10.1038/sj.bjc.6605287  0.392
2009 Rayoo M, Yan M, Takano EA, Bates GJ, Brown PJ, Banham AH, Fox SB. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. Journal of Clinical Pathology. 62: 896-902. PMID 19622517 DOI: 10.1136/jcp.2009.065169  0.365
2009 Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banham AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1046-51. PMID 19188178 DOI: 10.1158/1078-0432.CCR-08-1507  0.804
2009 Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, ... ... Fox SB, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer. 100: 405-11. PMID 19165203 DOI: 10.1038/sj.bjc.6604844  0.785
2009 Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 227-34. PMID 19064988 DOI: 10.1200/JCO.2007.13.7083  0.804
2009 Rayoo M, Yan M, Takano EA, Fox SB. BRCA1 associated breast cancers are frequently positive for ER and its cytoplasmic expression confers a poor prognosis Pathology. 41: 51. DOI: 10.1097/01268031-200941001-00102  0.375
2008 Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2673-80. PMID 18451231 DOI: 10.1158/1078-0432.CCR-07-1046  0.801
2008 Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nature Genetics. 40: 650-5. PMID 18408720 DOI: 10.1038/ng.117  0.33
2008 Shaida N, Launchbury R, Boddy JL, Jones C, Campo L, Turley H, Kanga S, Banham AH, Malone PR, Harris AL, Fox SB. Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. The Prostate. 68: 336-43. PMID 18163427 DOI: 10.1002/pros.20707  0.816
2008 Bates GJ, Fox SB, Han C, Launchbury R, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Research and Treatment. 111: 453-9. PMID 18026833 DOI: 10.1007/s10549-007-9812-4  0.748
2007 Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Research : Bcr. 9: 216. PMID 18190723 DOI: 10.1186/bcr1796  0.666
2007 Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Research : Bcr. 9: R89. PMID 18096060 DOI: 10.1186/bcr1838  0.789
2007 Gunningham SP, Currie MJ, Morrin HR, Tan EY, Turley H, Dachs GU, Watson AI, Frampton C, Robinson BA, Fox SB. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. The Journal of Pathology. 212: 335-44. PMID 17487938 DOI: 10.1002/path.2174  0.649
2007 Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL, Fox SB. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. The Prostate. 67: 1091-8. PMID 17477366 DOI: 10.1002/pros.20583  0.821
2007 Fox SB, Launchbury R, Bates GJ, Han C, Shaida N, Malone PR, Harris AL, Banham AH. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. The Prostate. 67: 623-9. PMID 17328069 DOI: 10.1002/pros.20538  0.409
2007 Generali D, Fox SB, Berruti A, Moore JW, Brizzi MP, Patel N, Allevi G, Bonardi S, Aguggini S, Bersiga A, Campo L, Dogliotti L, Bottini A, Harris AL. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 550-8. PMID 17255277 DOI: 10.1158/1078-0432.CCR-06-1266  0.796
2007 Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 467-74. PMID 17255267 DOI: 10.1158/1078-0432.CCR-06-1466  0.8
2007 Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P, Harris AL. EGFR mutations in exons 18-21 in sporadic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 203-5. PMID 17220285 DOI: 10.1093/annonc/mdl322  0.737
2007 Lau YS, Danks L, Sun SG, Fox S, Sabokbar A, Harris A, Athanasou NA. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Research and Treatment. 105: 7-16. PMID 17151927 DOI: 10.1007/s10549-006-9438-y  0.357
2007 Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4562-8. PMID 16899602 DOI: 10.1158/1078-0432.CCR-05-2690  0.822
2007 Generali DG, Berruti A, Fox SB, Brizzi M, Bonardi S, Milani M, Bersiga A, Dionisio R, Dogliotti L, Bottini A, Harris AL. Down-regulation of HIF-1α expression by letrozole in ER+ve breast cancer patients Journal of Clinical Oncology. 25: 510-510. DOI: 10.1200/JCO.2007.25.18_SUPPL.510  0.782
2007 Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First International Consensus on the Methodology of Lymphangiogenesis Quantification in Solid Human Tumors Cheminform. 38. DOI: 10.1002/CHIN.200725276  0.319
2006 Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5373-80. PMID 17135638 DOI: 10.1200/JCO.2006.05.9584  0.736
2006 Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer. 95: 1611-25. PMID 17117184 DOI: 10.1038/Sj.Bjc.6603445  0.422
2006 Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer. 13: 921-30. PMID 16954440 DOI: 10.1677/erc.1.01216  0.83
2006 Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3623-8. PMID 16877730 DOI: 10.1200/JCO.2005.04.5773  0.777
2006 Bacon AL, Fox S, Turley H, Harris AL. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene. 26: 132-41. PMID 16799636 DOI: 10.1038/sj.onc.1209761  0.794
2006 Fox SB. Quantitative angiogenesis in breast cancer. Methods in Molecular Medicine. 120: 161-87. PMID 16491601 DOI: 10.1385/1-59259-969-9:161  0.346
2006 Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute. 98: 262-72. PMID 16478745 DOI: 10.1093/jnci/djj052  0.516
2006 Generali DG, Fox S, Buffa FM, Berruti A, Brizzi M, Allevi G, Bonardi S, Dogliotti L, Bottini A, Harris A. Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients Journal of Clinical Oncology. 24: 618-618. DOI: 10.1200/jco.2006.24.18_suppl.618  0.593
2006 Sooriakumaran P, Macanas-Pirard P, Fox S, Coley H, Bucca G, Lovell D, Henderson A, Smith C, Langley S, Laing R. A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer Journal of Clinical Oncology. 24: 4563-4563. DOI: 10.1200/JCO.2006.24.18_SUPPL.4563  0.314
2005 Ah-See ML, Burcombe RJ, Daley FM, Richman PI, Padhani AR, Bentzen SM, Fox SB, Harris AL, Makris A. Evaluation of tumour microvessel density & pericyte coverage index following neoadjuvant chemotherapy in primary breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 655. PMID 27946122 DOI: 10.1200/Jco.2005.23.16_Suppl.655  0.531
2005 Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer Clinical Cancer Research. 11: 7658-7663. PMID 16278385 DOI: 10.1158/1078-0432.CCR-05-0460  0.811
2005 Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Research and Treatment. 93: 237-46. PMID 16172796 DOI: 10.1007/S10549-005-5157-Z  0.496
2005 Campo L, Turley H, Han C, Pezzella F, Gatter KC, Harris AL, Fox SB. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. The Journal of Pathology. 205: 585-91. PMID 15776477 DOI: 10.1002/path.1740  0.797
2005 Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 112: 413-30. PMID 15563306 DOI: 10.1111/j.1600-0463.2004.apm11207-0803.x  0.427
2005 Boddy J, Fox S, Cheng H, Hurley H, Brown P, Malone P, Banham A, Harris A. 885Co-expression of the forkhead transcription factor, FOXPI with the androgen receptor in human prostate cancer, support its role as a potential co-regulator of this receptor European Urology Supplements. 4: 224. DOI: 10.1016/S1569-9056(05)80889-9  0.751
2005 Boddy JL, Fox SB, Cheng H, Hurley H, Brown P, Malone PR, Harris AL. 237: Expression of the Androgen Receptor in Prostate Cancer is related to Vascular Endothelial Growth Factor and Hypoxia Inducible Factors 1: and 2 Journal of Urology. 173: 65-65. DOI: 10.1016/s0022-5347(18)34502-6  0.774
2004 Sotiriou C, Paesmans M, Harris A, Colozza MA, Fox S, Taylor M, Sorre A, Martiat P, Cardoso F, Piccart M. Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9504. PMID 28016802 DOI: 10.1200/jco.2004.22.14_suppl.9504  0.333
2004 Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7965-71. PMID 15585631 DOI: 10.1158/1078-0432.Ccr-04-0063  0.699
2004 Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Research. 64: 6563-70. PMID 15374969 DOI: 10.1158/0008-5472.CAN-03-3176  0.773
2004 Fox SB, Bragança J, Turley H, Campo L, Han C, Gatter KC, Bhattacharya S, Harris AL. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Research. 64: 6075-81. PMID 15342390 DOI: 10.1158/0008-5472.Can-04-0708  0.723
2004 Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, Fox SB. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. British Journal of Cancer. 91: 954-8. PMID 15328513 DOI: 10.1038/sj.bjc.6602059  0.743
2004 Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, Robinson BA, Fox SB. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. Journal of Clinical Pathology. 57: 829-34. PMID 15280403 DOI: 10.1136/jcp.2003.015644  0.345
2004 Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3521-7. PMID 15161711 DOI: 10.1158/1078-0432.CCR-03-0461  0.731
2004 Fox SB, Turley H, Cheale M, Blázquez C, Roberts H, James N, Cook N, Harris A, Gatter K. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. The Journal of Pathology. 202: 313-20. PMID 14991896 DOI: 10.1002/path.1520  0.657
2004 Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C, Harris AL. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. The Journal of Pathology. 201: 573-80. PMID 14648660 DOI: 10.1002/path.1486  0.784
2004 Ord JJ, Cranston D, Harris AL, Campo L, Turley H, Allen P, Fox S, Davies DR. 773: C-KIT and CK7 Immunohistochemistry in the Differential Diagnosis of Renal Cell Carcinoma, A Study of 111 Cases Journal of Urology. 171: 205-205. DOI: 10.1016/s0022-5347(18)38022-4  0.582
2003 Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Research and Treatment. 81: 137-47. PMID 14572156 DOI: 10.1023/A:1025702330207  0.497
2003 Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America. 100: 10393-8. PMID 12917485 DOI: 10.1073/Pnas.1732912100  0.462
2003 Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. The Journal of Pathology. 200: 183-94. PMID 12754739 DOI: 10.1002/path.1339  0.8
2003 Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. British Journal of Cancer. 88: 718-25. PMID 12618881 DOI: 10.1038/sj.bjc.6600807  0.551
2002 Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, Chong W, Harris AL, Fox SB. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. The Journal of Pathology. 198: 502-10. PMID 12434420 DOI: 10.1002/path.1228  0.791
2002 Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. European Journal of Cancer (Oxford, England : 1990). 38: 1564-79. PMID 12142044  0.338
2002 Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. The Lancet. Oncology. 2: 278-89. PMID 11905783 DOI: 10.1016/S1470-2045(00)00323-5  0.465
2001 Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. The Journal of Pathology. 195: 236-43. PMID 11592104 DOI: 10.1002/path.931  0.539
2001 Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. The Journal of Pathology. 193: 325-32. PMID 11241411 DOI: 10.1002/path.814  0.536
2000 Kakolyris S, Fox SB, Koukourakis M, Giatromanolaki A, Brown N, Leek RD, Taylor M, Leigh IM, Gatter KC, Harris AL. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. British Journal of Cancer. 82: 844-51. PMID 10732757 DOI: 10.1054/bjoc.1999.1010  0.547
2000 Fox SB, Gatter KC, Leek RD, Harris AL, Chew KL, Mayall BH, Moore DH. More about: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. Journal of the National Cancer Institute. 92: 161-2. PMID 10639519 DOI: 10.1093/jnci/92.2.161  0.705
1999 Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 10: 707-13. PMID 10442194 DOI: 10.1023/A:1008303614441  0.54
1998 Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. British Journal of Cancer. 77: 2246-51. PMID 9649140 DOI: 10.1038/bjc.1998.373  0.713
1998 Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID, Gatter KC, Harris AL. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. British Journal of Cancer. 77: 1169-73. PMID 9569057 DOI: 10.1038/bjc.1998.194  0.533
1997 Fox SB, Harris AL. The epidermal growth factor receptor in breast cancer Journal of Mammary Gland Biology and Neoplasia. 2: 131-141. PMID 10882299  0.476
1997 Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. The Journal of Pathology. 182: 414-20. PMID 9306962 DOI: 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q  0.586
1997 Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. Journal of the National Cancer Institute. 89: 1044-9. PMID 9230886 DOI: 10.1093/JNCI/89.14.1044  0.702
1997 Fox SB, Harris AL. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy Investigational New Drugs. 15: 15-28. PMID 9195286 DOI: 10.1023/A:1005714527315  0.427
1997 Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 8: 271-5. PMID 9137797 DOI: 10.1023/A:1008280110558  0.698
1997 Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. The Journal of Pathology. 181: 207-12. PMID 9120727 DOI: 10.1002/(SICI)1096-9896(199702)181:2<207::AID-PATH758>3.0.CO;2-4  0.484
1997 Engels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. Exs. 79: 113-56. PMID 9002231 DOI: 10.1007/978-3-0348-9006-9_6  0.501
1997 Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Human Pathology. 27: 1149-55. PMID 8912823 DOI: 10.1016/S0046-8177(96)90307-X  0.766
1996 Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. European Journal of Cancer (Oxford, England : 1990). 32: 2474-84. PMID 9059336 DOI: 10.1016/S0959-8049(96)00379-6  0.535
1996 Harris AL, Zhang H, Moghaddam A, Fox S, Scott P, Pattison A, Gatter K, Stratford I, Bicknell R. Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment. 38: 97-108. PMID 8825127 DOI: 10.1007/BF01803788  0.535
1996 Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. The Journal of Pathology. 179: 232-7. PMID 8774475 DOI: 10.1002/(sici)1096-9896(199607)179:3<232::aid-path505>3.0.co;2-a  0.399
1996 Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. British Journal of Cancer. 73: 275-80. PMID 8562330 DOI: 10.1038/bjc.1996.49  0.727
1996 Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. The Journal of Pathology. 177: 275-83. PMID 8551390 DOI: 10.1002/PATH.1711770310  0.71
1996 Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Research and Treatment. 36: 219-26. PMID 8534869 DOI: 10.1007/BF00666042  0.694
1995 Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. The Journal of Urology. 154: 237-41. PMID 7776437 DOI: 10.1016/S0022-5347(01)67286-0  0.445
1995 Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. The Journal of Pathology. 176: 183-90. PMID 7636628 DOI: 10.1002/path.1711760212  0.622
1995 Harris AL, Fox S, Leek R, Zhang H, Scott P, Bicknell R, Gatter K. Breast cancer angiogenesis: therapy target and prognostic factor. European Journal of Cancer (Oxford, England : 1990). 831-2. PMID 7543767 DOI: 10.1016/0959-8049(95)00129-7  0.722
1995 Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 92: 998-1002. PMID 7532308 DOI: 10.1073/pnas.92.4.998  0.688
1995 Macaulay VM, Fox SB, Zhang H, Whitehouse RM, Leek RD, Gatter KC, Bicknell R, Harris AL. Breast cancer angiogenesis and tamoxifen resistance Endocrine Related Cancer. 2: 97-103. DOI: 10.1677/erc.0.0020097  0.707
1995 Caffo O, Barbareschi M, Veronese S, Pezzella F, Leek R, Fox S, Harris A, Dalla Palma P. 686 BCL2 expression in node-negative breast carcinoma: A study on a series of 190 cases with long-term follow-up European Journal of Cancer. 31: S143. DOI: 10.1016/0959-8049(95)95936-Z  0.751
1994 Harris AL, Fox S, Bicknell R, Leek R, Relf M, LeJeune S, Kaklamanis L. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer. 74: 1021-5. PMID 8039135 DOI: 10.1002/1097-0142(19940801)74:3+<1021::AID-CNCR2820741508>3.0.CO;2-1  0.717
1994 Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment. 29: 41-49. PMID 8018963 DOI: 10.1007/Bf00666180  0.456
1994 Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. British Journal of Urology. 74: 762-6. PMID 7530131 DOI: 10.1111/j.1464-410X.1994.tb07122.x  0.398
1994 Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment. 29: 109-116. PMID 7517221 DOI: 10.1007/Bf00666186  0.745
1993 Rogers S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptor in male breast carcinoma. Human Pathology. 24: 148-51. PMID 8381763 DOI: 10.1016/0046-8177(93)90293-p  0.331
1993 Fox S, Stuart N, Smith K, Brunner N, Harris A. High levels of uPA and PA1 are associated with highly angiogenic breast carcinomas The Breast. 2: 206. DOI: 10.1016/0960-9776(93)90148-9  0.453
1993 Fox S, Gatter K, Bicknell R, Going J, Cooke T, Harris A. Endothelial cell proliferation in human breast carcinoma The Breast. 2: 206. DOI: 10.1016/0960-9776(93)90147-8  0.485
1992 Fox SB, Rogers S, Day CA, Underwood JC. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. The Journal of Pathology. 166: 13-8. PMID 1538271 DOI: 10.1002/path.1711660104  0.341
1991 Fox SB, Day CA, Rogers S. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. Journal of Clinical Pathology. 44: 960-1. PMID 1684366 DOI: 10.1136/jcp.44.11.960  0.323
Show low-probability matches.